Former Chief Financial Officer · Prelude Therapeutics Inc (PRLD)

Brian Piper

A named executive officer of Prelude Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,908,023

Salary $389,458Stock awards $0

FY2020: $1,961,340

2nd of 4 named executive officers at Prelude Therapeutics by FY2021 total.

4 named officers on file for Prelude Therapeutics, FY2021

Brian Piper’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Prelude Therapeutics’s whole pay program stands against its peers

  • Prelude Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PRLD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A).

Free

Get Brian Piper’s full pay file as a PDF — free

More than this page: up to 10 years of Brian’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Brian Piper compensation by year

Prelude Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Prelude Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$328,942$389,458
Bonus$0$0
Stock awards$0$0
Option awards$1,471,410$2,518,565
Non-equity incentive$160,988$0
Pension and deferred compensation$0$0
All other$0$0
Total$1,961,340$2,908,023

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Prelude Therapeutics Inc DEF 14A filed April 29, 2022, accession 0001564590-22-016626, and prior-year filings.

How this page was built: the Prelude Therapeutics Inc filed document, accession 0001564590-22-016626. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

$2.0M
$2.9M
FY20
FY21
SalaryNon-equity incentiveOption awards

Prelude Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Krishna VaddiChief Executive Officer$7,034,114
Brian Piper · this pageFormer Chief Financial Officer$2,908,023
Peggy ScherleChief Scientific Officer$2,633,099
Andrew CombsEVP and Head of Chemistry$2,631,289

The full Prelude Therapeutics compensation record

free company brief

This page is one person within Prelude Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Prelude Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Brian Piper's compensation dossier · One-time report. No refunds.